Lupin (LUPIN)₹2,025+1.40%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Lupin reported sales of ₹8,288 Cr, up 32.1% from Jun 2025, and net profit of ₹1,416 Cr, up 16.2% year on year. For the year to Mar 2026, sales were ₹28,016 Cr and net profit ₹5,347 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5,051 | 5,205 | 4,965 | 5,607 | 5,679 | 5,778 | 5,671 | 6,275 | 7,063 | 7,180 | 7,490 | 8,288 |
| Expenses | 4,117 | 4,158 | 3,959 | 4,355 | 4,331 | 4,408 | 4,344 | 4,537 | 4,705 | 4,904 | 4,984 | 5,820 |
| Operating Profit | 919 | 1,039 | 998 | 1,242 | 1,341 | 1,358 | 1,322 | 1,729 | 2,344 | 2,263 | 2,489 | 2,452 |
| OPM % | 18.0% | 20.0% | 20.0% | 22.0% | 24.0% | 24.0% | 23.0% | 28.0% | 33.0% | 32.0% | 33.0% | 30.0% |
| Other Income | 39.86 | 28.88 | 28.87 | 67.78 | 41.88 | 53.83 | 56.82 | 78.66 | 89.73 | −311 | 8.97 | 129 |
| Interest | 80.79 | 73.78 | 70.79 | 67.81 | 70.79 | 66.83 | 88.71 | 91.80 | 108 | 115 | 120 | 110 |
| Depreciation | 247 | 256 | 455 | 247 | 256 | 270 | 391 | 298 | 316 | 312 | 445 | 451 |
| Profit before tax | 631 | 736 | 498 | 993 | 1,056 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,927 | 2,017 |
| Tax % | 21.0% | 16.0% | 26.0% | 19.0% | 19.0% | 20.1% | 13.1% | 14.0% | 26.1% | 22.0% | 24.0% | 30.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −332 | −97.38 | 0.00 |
| Net Profit | 494 | 618 | 367 | 804 | 858 | 857 | 781 | 1,219 | 1,483 | 1,179 | 1,467 | 1,416 |
| EPS (Rs) | 10.77 | 13.48 | 7.90 | 17.59 | 18.72 | 18.77 | 16.93 | 26.73 | 32.40 | 25.77 | 31.96 | 31.01 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14,267 | 17,391 | 15,824 | 14,698 | 15,401 | 15,180 | 16,441 | 16,681 | 20,026 | 22,726 | 28,016 | 30,022 |
| Expenses | 10,563 | 12,850 | 12,641 | 12,106 | 13,005 | 12,591 | 16,177 | 14,903 | 16,189 | 17,420 | 19,778 | 20,412 |
| Operating Profit | 3,697 | 4,509 | 3,153 | 2,564 | 2,356 | 2,570 | 219 | 1,722 | 3,804 | 5,281 | 8,170 | 9,548 |
| OPM % | 26.0% | 26.0% | 20.0% | 17.0% | 15.0% | 17.0% | 1.3% | 10.0% | 19.0% | 23.0% | 29.0% | 31.8% |
| Other Income | 183 | 106 | −1,306 | 90.66 | −134 | 138 | 209 | 150 | 130 | 201 | 521 | −82.79 |
| Interest | 58.86 | 153 | 203 | 301 | 362 | 141 | 143 | 273 | 311 | 294 | 433 | 452 |
| Depreciation | 485 | 909 | 1,082 | 843 | 966 | 884 | 1,654 | 877 | 1,193 | 1,164 | 1,371 | 1,525 |
| Profit before tax | 3,328 | 3,545 | 548 | 1,503 | 888 | 1,677 | −1,373 | 717 | 2,421 | 4,016 | 6,870 | 7,473 |
| Tax % | 32.0% | 28.1% | 53.0% | 59.0% | 130.0% | 27.0% | 10.0% | 38.1% | 20.0% | 18.1% | 22.0% | — |
| Exceptional items | 7.03 | −6.03 | −30.13 | −123 | 202 | 39.12 | 33.12 | 20.09 | 23.07 | 57.26 | −356 | −430 |
| Net Profit | 2,266 | 2,562 | 258 | 614 | −270 | 1,227 | −1,527 | 447 | 1,932 | 3,303 | 5,347 | 5,545 |
| EPS (Rs) | 50.21 | 56.68 | 5.57 | 13.41 | −5.96 | 26.85 | −33.68 | 9.46 | 42.08 | 71.94 | 116.72 | 121.14 |
| Dividend payout % | 15.1% | 13.0% | 90.1% | 37.0% | −101.0% | 24.1% | −11.9% | 42.1% | 19.0% | 17.1% | 15.1% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 89.84 | 89.84 | 89.82 | 89.84 | 89.84 | 90.85 | 90.84 | 90.86 | 90.79 | 90.88 | 90.89 | 90.83 |
| Reserves | 8,805 | 11,091 | 13,420 | 13,511 | 13,674 | 12,472 | 13,745 | 12,087 | 12,396 | 14,230 | 17,151 | 22,406 |
| Borrowings | 539 | 7,194 | 7,973 | 7,159 | 8,513 | 6,322 | 4,800 | 4,171 | 4,556 | 2,930 | 5,469 | 6,634 |
| Other Liabilities | 3,625 | 3,938 | 4,726 | 5,275 | 5,397 | 5,939 | 4,821 | 5,330 | 5,780 | 6,512 | 6,308 | 9,038 |
| Total Liabilities | 13,060 | 22,313 | 26,209 | 26,035 | 27,674 | 24,824 | 23,457 | 21,680 | 22,821 | 23,764 | 29,019 | 38,169 |
| Fixed Assets | 4,359 | 8,697 | 11,002 | 10,335 | 11,052 | 7,911 | 7,866 | 7,368 | 8,337 | 8,849 | 9,700 | 10,958 |
| CWIP | 577 | 2,709 | 2,137 | 2,601 | 1,644 | 941 | 1,069 | 1,148 | 1,239 | 774 | 518 | 1,017 |
| Investments | 1,654 | 15.96 | 2,133 | 262 | 2,290 | 2,369 | 2,450 | 899 | 516 | 1,073 | 1,144 | 3,663 |
| Other Assets | 6,469 | 10,890 | 10,937 | 12,837 | 12,688 | 13,602 | 12,072 | 12,266 | 12,729 | 13,069 | 17,657 | 22,531 |
| Inventories | 2,505 | 3,276 | 3,643 | 3,666 | 3,839 | 3,459 | 4,096 | 4,634 | 4,494 | 4,957 | 5,477 | 6,089 |
| Trade receivables | 2,666 | 4,563 | 4,322 | 5,207 | 5,167 | 5,465 | 4,487 | 4,279 | 4,494 | 4,709 | 5,516 | 6,632 |
| Cash & equivalents | 480 | 820 | 697 | 1,406 | 985 | 2,449 | 1,738 | 1,096 | 1,289 | 1,200 | 3,133 | 5,639 |
| Total Assets | 13,060 | 22,313 | 26,209 | 26,035 | 27,674 | 24,824 | 23,457 | 21,680 | 22,821 | 23,764 | 29,019 | 38,169 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 2,742 | −384 | 4,127 | 1,756 | 1,671 | 1,474 | 1,829 | 368 | 1,903 | 3,658 | 3,009 | 7,355 |
| Cash from investing activity | −1,036 | −6,781 | −2,531 | 471 | −3,290 | 1,110 | −1,243 | 1,295 | −1,291 | −1,715 | −4,180 | −3,876 |
| Cash from financing activity | −197 | 5,849 | 434 | −1,495 | 745 | −892 | −1,889 | −1,576 | −338 | −2,187 | 1,736 | −847 |
| Net cash flow | 1,501 | −1,315 | 2,018 | 729 | −872 | 1,685 | −1,302 | 87.03 | 273 | −248 | 559 | 2,622 |
| Capex | 873 | 5,839 | 2,645 | 1,556 | 988 | 675 | 679 | 908 | 1,503 | 932 | 1,686 | 2,059 |
| Free cash flow | 1,866 | −6,163 | 1,512 | 261 | 706 | 798 | 1,150 | −531 | 436 | 2,731 | 1,348 | 5,524 |
| CFO / OP % | 101.0% | 21.0% | 117.0% | 73.0% | 102.0% | 84.0% | 99.0% | 146.0% | 124.0% | 105.0% | 74.0% | 105.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 | 86 |
| Inventory days | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 | 303 |
| Days payable | 173 | 169 | 190 | 179 | 185 | 163 | 138 | 130 | 137 | 164 | 159 | 209 |
| Cash conversion cycle | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 | 181 |
| Working capital days | 56 | 102 | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 | 28 |
| ROCE % | 40.0% | 23.9% | 18.9% | 9.9% | 9.9% | 8.9% | 9.0% | −7.0% | 6.0% | 16.0% | 20.9% | 29.9% |
For the Jun 2026 quarter, Lupin reported sales of ₹8,288 Cr, up 32.1% year on year and net profit of ₹1,416 Cr, up 16.2% year on year. The operating margin was 30.0%.
Lupin's sales for the year to Mar 2026 were ₹28,016 Cr; over the last twelve months they were ₹30,022 Cr.
Net profit for the year to Mar 2026 was ₹5,347 Cr, and ₹5,545 Cr over the last twelve months. Earnings per share over the same trailing period were ₹121.14.
Lupin reported borrowings of ₹6,634 Cr at Mar 2026, against cash and equivalents of ₹5,639 Cr.
Cash from operations was ₹7,355 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹5,524 Cr.